Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05815485 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
A Phase 2 study of COVID-19, sponsored by The University of Texas Medical Branch, Galveston.
- Active
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 3
- Study locations
NCT05815485 is a Phase 2 study of COVID-19 that is active but no longer recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 144 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05815485, a Phase 2 study of COVID-19, is active but no longer recruiting, sponsored by The University of Texas Medical Branch, Galveston.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 3
- Study locations
Study Summary
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azeliragon
Study Locations (3)
Illinois
- Rush University - Chicago
Michigan
- University of Michigan - Ann Arbor
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05815485
The ClinicalTrials.gov registry entry for NCT05815485 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05815485 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT05815485 about?
NCT05815485 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia". A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.
What is the current status of trial NCT05815485?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2023-05-04. Estimated completion is 2026-04.
What conditions does trial NCT05815485 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05815485?
The interventions under investigation include: Placebo (DRUG), Azeliragon (DRUG).
Who is sponsoring clinical trial NCT05815485?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05815485 being conducted?
This trial has 3 study locations across Illinois, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.